Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response.

De Smedt E, Lui H, Maes K, De Veirman K, Menu E, Vanderkerken K, De Bruyne E.

Front Oncol. 2018 Dec 11;8:566. doi: 10.3389/fonc.2018.00566. eCollection 2018. Review.

2.

Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.

De Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, Vlummens P, Fostier K, Kassambara A, Moreaux J, Van Ginderachter JA, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Cancer Lett. 2019 Feb 1;442:233-241. doi: 10.1016/j.canlet.2018.11.002. Epub 2018 Nov 9.

PMID:
30419344
3.

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.

Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, Heusschen R, De Raeve H, Schots R, Vanderkerken K, Caers J, Menu E.

Blood Cancer J. 2018 Nov 8;8(11):105. doi: 10.1038/s41408-018-0139-7.

4.

The genetic landscape of 5T models for multiple myeloma.

Maes K, Boeckx B, Vlummens P, De Veirman K, Menu E, Vanderkerken K, Lambrechts D, De Bruyne E.

Sci Rep. 2018 Oct 9;8(1):15030. doi: 10.1038/s41598-018-33396-w.

5.

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects.

De Beck L, Melhaoui S, De Veirman K, Menu E, De Bruyne E, Vanderkerken K, Breckpot K, Maes K.

Oncoimmunology. 2018 Jul 23;7(10):e1484981. doi: 10.1080/2162402X.2018.1484981. eCollection 2018.

6.

Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?

Venken K, Favreau M, Gaublomme D, Menu E, Vanderkerken K, Elewaut D.

Mol Immunol. 2018 Sep;101:521-526. doi: 10.1016/j.molimm.2018.08.019. Epub 2018 Aug 25.

PMID:
30153633
7.

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

De Beule N, Menu E, Bertrand MJM, Favreau M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez S, Vanderkerken K, De Trez C.

Oncotarget. 2018 Apr 27;9(32):22871. doi: 10.18632/oncotarget.25336. eCollection 2018 Apr 27.

8.

Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study.

Rao L, De Veirman K, Giannico D, Saltarella I, Desantis V, Frassanito MA, Solimando AG, Ribatti D, Prete M, Harstrick A, Fiedler U, De Raeve H, Racanelli V, Vanderkerken K, Vacca A.

Oncotarget. 2018 Jan 30;9(17):13366-13381. doi: 10.18632/oncotarget.24351. eCollection 2018 Mar 2.

9.

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?

Xu S, De Veirman K, De Becker A, Vanderkerken K, Van Riet I.

Leukemia. 2018 Jul;32(7):1500-1514. doi: 10.1038/s41375-018-0061-9. Epub 2018 Feb 22. Review.

10.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

PMID:
29500406
11.

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, Robert N, Heirman C, Cakana A, Hose D, Breckpot K, van Grunsven LA, De Veirman K, Menu E, Vanderkerken K, Moreaux J, De Bruyne E.

Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19.

PMID:
29259009
12.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E.

Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13.

13.

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

De Beule N, Menu E, Bertrand MJM, Favreau M, De Bruyne E, Maes K, De Veirman K, Radwanska M, Samali A, Magez S, Vanderkerken K, De Trez C.

Oncotarget. 2017 May 24;8(32):52016-52025. doi: 10.18632/oncotarget.18152. eCollection 2017 Aug 8. Erratum in: Oncotarget. 2018 Apr 27;9(32):22871.

14.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.

15.

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.

Favreau M, Menu E, Gaublomme D, Vanderkerken K, Faict S, Maes K, De Bruyne E, Govindarajan S, Drennan M, Van Calenbergh S, Leleu X, Zabeau L, Tavernier J, Venken K, Elewaut D.

Leukemia. 2017 Dec;31(12):2678-2685. doi: 10.1038/leu.2017.146. Epub 2017 May 11.

PMID:
28490813
16.

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition.

Favreau M, Venken K, Faict S, Maes K, De Veirman K, De Bruyne E, Leleu X, Boon L, Elewaut D, Vanderkerken K, Menu E.

Haematologica. 2017 Jul;102(7):e266-e270. doi: 10.3324/haematol.2017.163758. Epub 2017 Apr 6. No abstract available.

17.

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.

De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K.

J Pathol. 2017 Mar;241(4):534-546. doi: 10.1002/path.4860. Epub 2017 Jan 30.

PMID:
27976373
18.

RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.

Hofman IJF, van Duin M, De Bruyne E, Fancello L, Mulligan G, Geerdens E, Garelli E, Mancini C, Lemmens H, Delforge M, Vandenberghe P, Wlodarska I, Aspesi A, Michaux L, Vanderkerken K, Sonneveld P, De Keersmaecker K.

Leukemia. 2017 Aug;31(8):1706-1714. doi: 10.1038/leu.2016.370. Epub 2016 Dec 2.

19.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.

Haematologica. 2016 Dec;101(12):1451-1459. Epub 2016 Nov 10. Review.

20.

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.

Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots R, Vanderkerken K, Menu E.

Oncotarget. 2016 Jun 21;7(25):38927-38945. doi: 10.18632/oncotarget.7792. Review.

21.

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Bieghs L, Johnsen HE, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, Nyegaard M, Conover CA, Vanderkerken K, De Bruyne E.

Oncotarget. 2016 Jul 26;7(30):48732-48752. doi: 10.18632/oncotarget.8982. Review.

22.

Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.

Bieghs L, Brohus M, Kristensen IB, Abildgaard N, Bøgsted M, Johnsen HE, Conover CA, De Bruyne E, Vanderkerken K, Overgaard MT, Nyegaard M.

PLoS One. 2016 Apr 25;11(4):e0154256. doi: 10.1371/journal.pone.0154256. eCollection 2016.

23.

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I.

Cancer Lett. 2016 Jul 10;377(1):17-24. doi: 10.1016/j.canlet.2016.04.024. Epub 2016 Apr 19.

PMID:
27102001
24.

A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.

Rasche L, Menoret E, Dubljevic V, Menu E, Vanderkerken K, Lapa C, Steinbrunn T, Chatterjee M, Knop S, Düll J, Greenwood DL, Hensel F, Rosenwald A, Einsele H, Brändlein S.

Clin Cancer Res. 2016 Sep 1;22(17):4341-9. doi: 10.1158/1078-0432.CCR-15-3111. Epub 2016 Mar 30.

25.

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Favreau M, Vanderkerken K, Elewaut D, Venken K, Menu E.

Oncotarget. 2016 Apr 26;7(17):23128-40. doi: 10.18632/oncotarget.7440. Review.

26.

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.

Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Jan 26;7(4):4062-76. doi: 10.18632/oncotarget.6768.

27.

Novel strategies to target the ubiquitin proteasome system in multiple myeloma.

Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Feb 9;7(6):6521-37. doi: 10.18632/oncotarget.6658. Review.

28.

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.

Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI.

Nat Commun. 2015 Dec 3;6:8983. doi: 10.1038/ncomms9983.

29.

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.

Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E.

Oncotarget. 2015 Dec 22;6(41):43992-4004. doi: 10.18632/oncotarget.6083.

30.

Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.

Frassanito MA, De Veirman K, Desantis V, Di Marzo L, Vergara D, Ruggieri S, Annese T, Nico B, Menu E, Catacchio I, Ria R, Racanelli V, Maffia M, Angelucci E, Derudas D, Fumarulo R, Dammacco F, Ribatti D, Vanderkerken K, Vacca A.

Leukemia. 2016 Mar;30(3):640-8. doi: 10.1038/leu.2015.289. Epub 2015 Oct 21.

PMID:
26487273
31.

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.

Fristedt Duvefelt C, Lub S, Agarwal P, Arngården L, Hammarberg A, Maes K, Van Valckenborgh E, Vanderkerken K, Jernberg Wiklund H.

Oncotarget. 2015 Aug 21;6(24):20621-35.

32.

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.

De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2015 Apr 30;6(12):10532-47.

33.

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E.

Oncotarget. 2015 Feb 20;6(5):3319-34.

34.

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.

De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA.

Front Oncol. 2014 Dec 8;4:349. doi: 10.3389/fonc.2014.00349. eCollection 2014. Review.

35.

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.

Nur H, Rao L, Frassanito MA, De Raeve H, Ribatti D, Mfopou JK, Van Valckenborgh E, De Bruyne E, Vacca A, Vanderkerken K, Menu E.

Br J Haematol. 2014 Dec;167(5):651-63. doi: 10.1111/bjh.13092. Epub 2014 Aug 21.

PMID:
25142285
36.

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.

Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, Nyegaard M, Schots R, Jernberg-Wiklund H, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 Nov 30;5(22):11193-208.

37.

Cancer associated fibroblasts and tumor growth: focus on multiple myeloma.

De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A, Vanderkerken K.

Cancers (Basel). 2014 Jun 27;6(3):1363-81. doi: 10.3390/cancers6031363.

38.

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K, Menu E.

Blood. 2014 Jul 24;124(4):555-66. doi: 10.1182/blood-2014-03-562439. Epub 2014 Jun 13.

39.

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.

Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, McClue S, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 May 30;5(10):3115-29.

40.

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

PLoS One. 2013 Nov 6;8(11):e79752. doi: 10.1371/journal.pone.0079752. eCollection 2013.

41.

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E.

Cancers (Basel). 2013 Apr 15;5(2):430-61. doi: 10.3390/cancers5020430.

42.

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.

Lemaire M, D'Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, Kronenberger P, Wernery U, Muyldermans S, Devoogdt N, Vanderkerken K.

Leukemia. 2014 Feb;28(2):444-7. doi: 10.1038/leu.2013.292. Epub 2013 Oct 9. No abstract available.

PMID:
24166214
43.

Vorinostat-induced bone loss might be related to drug toxicity.

Xu S, De Veirman K, Vanderkerken K, Van Riet I.

Bone. 2013 Dec;57(2):384-5. doi: 10.1016/j.bone.2013.08.024. Epub 2013 Aug 30. No abstract available.

PMID:
23999199
44.

Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.

Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, Racanelli V, Catacchio I, Berardi S, Basile A, Menu E, Ruggieri S, Nico B, Ribatti D, Fumarulo R, Dammacco F, Vanderkerken K, Vacca A.

Leukemia. 2014 Apr;28(4):904-16. doi: 10.1038/leu.2013.254. Epub 2013 Sep 2.

PMID:
23995611
45.

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K.

Mol Cancer Ther. 2013 Sep;12(9):1763-73. doi: 10.1158/1535-7163.MCT-13-0123. Epub 2013 Jul 5. Erratum in: Mol Cancer Ther. 2015 Jul;14(7):1762. De Bryune, Elke [Corrected to De Bruyne, Elke].

46.

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.

Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E.

PLoS One. 2013 May 31;8(5):e65075. doi: 10.1371/journal.pone.0065075. Print 2013.

47.

Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors.

Otjacques E, Binsfeld M, Rocks N, Blacher S, Vanderkerken K, Noel A, Beguin Y, Cataldo D, Caers J.

PLoS One. 2013 May 7;8(5):e62818. doi: 10.1371/journal.pone.0062818. Print 2013.

48.

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, Van Riet I.

Acta Pharmacol Sin. 2013 May;34(5):699-709. doi: 10.1038/aps.2012.182. Epub 2013 Apr 8.

49.

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

Hu J, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K.

Dis Model Mech. 2012 Nov;5(6):763-71. doi: 10.1242/dmm.008961. Review.

50.

Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.

Xu D, Hu J, De Bruyne E, Menu E, Schots R, Vanderkerken K, Van Valckenborgh E.

Biochem Biophys Res Commun. 2012 Nov 30;428(4):518-24. doi: 10.1016/j.bbrc.2012.10.071. Epub 2012 Oct 27.

PMID:
23111325

Supplemental Content

Loading ...
Support Center